Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

Ribas, Antoni; Hodi, F. Stephen; Callahan, Margaret K.; Konto, Cyril; Wolchok, Jedd D.

doi:10.1056/nejmc1302338

letterNew England Journal of MedicineApr 3, 2013Closed access

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

ARAntoni Ribas FSF. Stephen Hodi MKMargaret K. Callahan CKCyril Konto JDJedd D. Wolchok

University of California, Los Angeles · Dana-Farber Cancer Institute · +3 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

The independent mechanisms of action and largely nonoverlapping toxicity profiles of vemurafenib and ipilimumab made it logical to test them together in a study of patients with melanoma. An unexpected level of hepatic toxicity caused the early termination of the study.

Citation impact

701

total citations

FWCI: 52.95
Percentile: 100%
References: 5

Citations per year

Authors

AR
Antoni RibasCorresponding
University of California, Los Angeles
FS
F. Stephen Hodi
Dana-Farber Cancer Institute, Harvard University
MK
Margaret K. Callahan
Memorial Sloan Kettering Cancer Center
CK
Cyril Konto
Bristol-Myers Squibb (United States)
JD
Jedd D. Wolchok
Memorial Sloan Kettering Cancer Center

Topics & keywords

Topics

Melanoma and MAPK Pathways100%
Cutaneous Melanoma Detection and Management99%
Computational Drug Discovery Methods99%

Keywords

Vemurafenib
Medicine
Ipilimumab
Oncology
Dermatology
Internal medicine
Pharmacology
Cancer research

No related works found for this paper.